OXB–302

OXB–302

Acute Myeloid Leukaemia
Pre–Clinical

OXB–302

Gene-based immunotherapy targeting blood cancer

Status: Pre–Clinical complete

Immunotherapy
OXB-302 is our lead programme which targets 5T4, this is currently being investigated in Acute Myeloid Leukaemia.